Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 19/20 | 0.59 |
| ▸ | MMP3 | P08254 | 10/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | ANPEP | P15144 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6889052 | 0.87 | MMP8 (0.66) | MMP8MMP3 | |
| SCHEMBL6889057 | 0.87 | MMP8 (0.66) | MMP8MMP3 | |
| SCHEMBL6888715 | 0.86 | MMP8 (0.62) | MMP8MMP3MMP2ANPEP | |
| SCHEMBL31685897 | 0.83 | POLB (0.69) | MMP8MMP3 | |
| SCHEMBL26616335 | 0.83 | POLB (0.69) | MMP8MMP3 | |
| SCHEMBL26616325 | 0.83 | POLB (0.69) | MMP8MMP3 | |
| SCHEMBL5960179 | 0.83 | POLB (0.69) | MMP8MMP3 | |
| SCHEMBL6873972 | 0.81 | MMP8 (0.76) | MMP8MMP3MMP2ANPEP | |
| SCHEMBL14837362 | 0.80 | MMP8 (0.54) | MMP8MMP3 | |
| SCHEMBL6890721 | 0.79 | MMP8 (0.58) | MMP8MMP3MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716853-B2 | DEGENERATIVE JOINT DISORDERS; 2-(4'-ALKYLOXYCARBONYLAMINOBI PHENYL-4-SULFONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXY OR THE 4,5,6,7-TETRAHYDRO-1H-IMIDAZO(4,5-C)PYRIDINE RING; SULFONYLATION OF RING N WITH 4-NITROBIPHENYLSULFONIC ACID | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-04-06 | — | — | US | disclosed |
| US-20030199543-A1 | Cyclic N-substituted alpha-imino carboxylic acids for selective inhibition of collogenase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199543-A1 | Cyclic N-substituted alpha-imino carboxylic acids for selective inhibition of collogenase | MMP1, MMP13, TIMP3 | MMP8 13/4885MMP3 6/4885MMP2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.